Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The World Health Organisation (WHO) is calling for cigarette-style warnings on alcohol to raise awareness about the link ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Occupational studies stretching back decades have found an increased risk of bladder cancer among hairdressers.